Arovella Therapeutics Limited (AU:ALA)

ASX:ALA

ALA

Arovella Therapeutics Limited

RESEARCH TOOLSreports

Want to see AU:ALA full AI Analyst Report?

Arovella Therapeutics Limited (ALA) Price & Analysis

18 Followers

ALA Stock Chart & Stats

AU$0.08

AU$0.00(0.00%)

At close: Jan 07 4:00 PM EST

AU$0.08

AU$0.00(0.00%)

Day’s Range― - ―

52-Week RangeAU$0.07 - AU$0.13

Previous CloseN/A

Volume194.12K

Average Volume (3M)1.58M

Market Cap

AU$103.96M

Enterprise ValueAU$84.45M

Total Cash (Recent Filing)AU$19.37M

Total Debt (Recent Filing)AU$0.00

Price to Earnings (P/E)―

Beta1.73

Next Earnings

Sep 02, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)>-0.01

Shares Outstanding1,208,783,700

10 Day Avg. Volume1,549,358

30 Day Avg. Volume1,578,675

Financial Highlights & Ratios

PEG Ratio0.54

Price to Book (P/B)5.47

Price to Sales (P/S)806.87

P/FCF Ratio-14.94

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Balance Sheet StrengthArovella's virtually debt-free balance sheet and a materially stronger equity base (equity rose from ~3.8M in 2023 to ~20.1M in 2025) reduce interest and refinancing risk. This durable financial flexibility supports continued R&D spending and partnership options over the next several months.

Platform & Market PositioningThe company's focus on engineered immune-cell therapies (iNKT and CAR approaches) aligns with structural growth in cell-based oncology. These high-barrier science platforms create durable competitive advantages if clinical translation succeeds and make the firm an attractive partner or acquisition target.

Improving Gross Margin TrendA return to positive gross profit in 2025 signals that core program costs may be better aligned with revenues or grant income, reducing direct cost pressure. While operating losses persist, this improvement supports marginally better cash efficiency and scalability if revenue or program milestones progress.

Bears Say

Persistent Negative Cash FlowArovella consistently generates negative operating and free cash flow, indicating it is not self-funding. Over a 2-6 month horizon this persistent cash burn necessitates external financing or partnerships, elevating dilution risk and pressuring management to secure funding or slow program spending.

Small, Volatile RevenueThe company's revenue base is tiny and swung sharply down in 2025, demonstrating lack of commercial traction and high outcome volatility. This structural weakness means operations remain dependent on funding milestones and grants rather than predictable product sales, complicating long-term planning.

Sustained UnprofitabilityContinuous negative EBIT and net income across reported periods indicate profitability is distant absent major clinical or commercial breakthroughs. Persistent losses can erode equity over time and force strategic trade-offs between R&D pace and cash preservation, affecting long-term value creation.

Arovella Therapeutics Limited News

Arovella Boosts Cash Reserves with Additional R&D Tax Rebate

Arovella Therapeutics Limited ( ($AU:ALA) ) has shared an announcement. Arovella Therapeutics has received an additional A$0.28 million...

3d ago

Arovella Options Lapse, Simplifying Capital Structure

An update from Arovella Therapeutics Limited ( ($AU:ALA) ) is now available. Arovella Therapeutics Limited has announced the...

5d ago

Arovella Therapeutics Seeks ASX Quotation for 1.6 Million New Shares

Arovella Therapeutics Limited ( ($AU:ALA) ) has shared an announcement. Arovella Therapeutics has applied to the ASX for...

8d ago

Arovella issues 1.6m new shares and affirms regulatory compliance

Arovella Therapeutics Limited ( ($AU:ALA) ) has provided an update. Arovella Therapeutics has issued 1,600,000 new ordinary shares...

8d ago

Arovella Weighs Validity of Requisitioned Meeting for Board Appointments

Arovella Therapeutics Limited ( ($AU:ALA) ) has issued an update. Arovella Therapeutics has received a purported shareholder notice...

8d ago

Arovella’s ALA-101 Trial Moves Toward Launch In CD19 Blood Cancers

Arovella Therapeutics Limited ($AU:ALA) announced an update on their ongoing clinical study. The Phase 1 study “A Phase...

9d ago

ALA

Arovella’s Armoured CLDN18.2 CAR-iNKT Cells Show Strong Activity Against Gastric and Pancreatic Cancer In Vitro

Arovella Therapeutics Limited ( ($AU:ALA) ) has issued an update. Arovella Therapeutics has demonstrated that its novel CLDN18.2-targeting...

17d ago

Arovella Wins TGA Green Light to Run ALA-101 Cell Therapy Trial Under Streamlined CTN Pathway

Arovella Therapeutics Limited ( ($AU:ALA) ) has shared an announcement. Arovella Therapeutics has received confirmation from Australia’s Therapeutic...

1M ago

Arovella Therapeutics Announces Departure of Director Gary Phillips

Arovella Therapeutics Limited ( ($AU:ALA) ) has shared an update. Arovella Therapeutics Limited has disclosed that director Gary...

2M ago

Arovella reshapes board as CAR-iNKT cell therapy program advances

Arovella Therapeutics Limited ( ($AU:ALA) ) just unveiled an announcement. Arovella Therapeutics has announced the retirement of Interim...

2M ago

ALA FAQ

What was Arovella Therapeutics Limited’s price range in the past 12 months?

Arovella Therapeutics Limited lowest share price was AU$0.07 and its highest was AU$0.13 in the past 12 months.

What is Arovella Therapeutics Limited’s market cap?

Arovella Therapeutics Limited’s market cap is AU$103.96M.

When is Arovella Therapeutics Limited’s upcoming earnings report date?

Arovella Therapeutics Limited’s upcoming earnings report date is Sep 02, 2026 which is in 137 days.

How were Arovella Therapeutics Limited’s earnings last quarter?

Arovella Therapeutics Limited released its earnings results on Feb 19, 2026. The company reported -AU$0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.002.

Is Arovella Therapeutics Limited overvalued?

According to Wall Street analysts Arovella Therapeutics Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Arovella Therapeutics Limited pay dividends?

Arovella Therapeutics Limited does not currently pay dividends.

What is Arovella Therapeutics Limited’s EPS estimate?

Arovella Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Arovella Therapeutics Limited have?

Arovella Therapeutics Limited has 1,208,783,700 shares outstanding.

What happened to Arovella Therapeutics Limited’s price movement after its last earnings report?

Arovella Therapeutics Limited reported an EPS of -AU$0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.706%.

Which hedge fund is a major shareholder of Arovella Therapeutics Limited?

Currently, no hedge funds are holding shares in AU:ALA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Arovella Therapeutics Limited Stock Smart Score

Underperform

Fundamentals

Return on Equity

-40.65%

Trailing 12-Months

Asset Growth

60.08%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Arovella Therapeutics Limited

Arovella Therapeutics Limited, a biotechnology company, focuses on the development of therapies for the treatment of cancer and conditions that affect the central nervous system in Australia and internationally. Its product pipeline includes ZolpiMist, an oral spray of zolpidem tartrate to treat short-term insomnia, which is marketed under the brand name of Ambien or Stilnox; invariant natural killer T (iNKT), a cell therapy platform to treat blood cancer; OroMist, an oro-mucosal technology that delivers a range of drug classes through the cheeks, gums, tongue, or floor of the mouth; and Anagrelide to treat cancer. The company also develops oral sprays to treat migraine headaches, motion sickness, and drug-resistant epilepsy. It has a collaborative research agreement with Imperial College London. The company was formerly known as Suda Pharmaceuticals Ltd and changed its name to Arovella Therapeutics Limited in October 2021. Arovella Therapeutics Limited was incorporated in 1999 and is headquartered in Osborne Park, Australia.